TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06160089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoinertial training
Description: For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (inertial). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gravitational training
Description: For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (gravitational). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
Study: NCT02052986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VASCAZEN
Description: All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
Study: NCT05719194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard SBT
Description: Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBT with T-piece or PSV
Description: - Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.~If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.
Study: NCT06492434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer decision coaching
Description: Peer Decision Coaching is a brief, personalized intervention grounded in evidence-based decision- and peer support principles. During the intervention, a trained peer specialist supports the young person in identifying a decision related to community participation that they need to make, such as whether to work or go to school, helping them address decision-making needs, and assisting them with developing and implementing a decision-making plan. Ultimately, the intervention aims to support young people in pursuing their community participation interests and goals.
Study: NCT05291624

Intervention type: DIAGNOSTIC_TEST
Intervention: AAGL Endometriosis Classification score - ULTRASOUND
Description: At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification

Intervention type: DIAGNOSTIC_TEST
Intervention: AAGL Endometriosis Classification score - SURGERY
Description: Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification
Study: NCT05990725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab solution for injection administered subcutaneously.
Study: NCT05670743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride
Description: Topical application of 38% silver diamine fluoride to dental caries lesions
Study: NCT05341739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-operative Stereotactic Radiosurgery
Description: Pre-operative SRS will be performed prior to the surgical resection of the brain metastases.
Study: NCT06246487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Intervention
Description: Children randomized to the intervention condition will receive a sensory enriched intervention 2x's per week, 60-minutes per session, for 16 weeks. The intervention will follow a codified protocol developed by Dr. Bodison that is theoretically grounded in neurodevelopmental research. The interveners will be occupational therapists who will be trained by Dr. Bodison to deliver the codified, intervention protocol to provide a personally customized set of therapeutically guided environmental interactions. Because, at its core, the intervention emphasizes playful interaction with a sensory enriched environment, the intervention room will be equipped with swings, scooter boards, climbing equipment, bolsters, and large carpeted barrels. Within this setting, using the codified manual of intervention developed by Dr. Bodison, the intervener will structure activities to provide tactile and proprioceptive input to address the child's individualized areas of need.
Study: NCT06274931

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Through a bronchoscopic examination performed at the time of admission for diagnostic purposes, an alveolar bronchial lavage was performed for the analysis of the lung microbiome.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Through a bronchoscopic examination performed at the time of admission for diagnostic purposes, an alveolar bronchial lavage was performed for the analysis of the lung microbiome.
Study: NCT05378334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI
Description: PD-1 inhibitors selected by clinicians based on patients' condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICI
Description: PD-1 inhibitors selected by clinicians based on patients' condition
Study: NCT04804761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
Study: NCT05800756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib combined with trastuzumab, dalpiciclib and letrozole
Description: Six 4-week cycles of dalpiciclib orally, 125mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28, and pyrotinib orally, 320mg, day 1-28, and trastuzumab, injection, 8 mg/kg loading dose in cycle 1, 6mg/kg in cycles 2-6, intravenous drops, 1 cycle on day 1-21.
Study: NCT06065644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTMA
Description: Induced displacement of the Sacroiliac joint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CTMA
Description: Induced displacement of the Sacroiliac joint
Study: NCT05564481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes education and parent coaching support
Description: Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diabetes education and parent coaching support
Description: Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
Study: NCT05378334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone-protecting and Mass-dispersesing Decoction
Description: Chinese Herbal Formula,also named as HGXJT
Study: NCT05493293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-921352
Description: Tablets for oral administration
Study: NCT04799925

Intervention type: DRUG
Intervention: Febuxostat
Description: uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
Study: NCT06011434

Intervention type: BEHAVIORAL
Intervention: Mammography Screening Conversation Aid
Description: Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points.

Intervention type: BEHAVIORAL
Intervention: Mammography Screening Conversation Aid
Description: Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points.

Intervention type: BEHAVIORAL
Intervention: Mammography Screening Conversation Aid
Description: Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points.
Study: NCT05245383

Intervention type: OTHER
Group type: OTHER
Intervention: ten products (S01~S10) and two blank (BK1, BK2)
Description: S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back.
Study: NCT05611112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.
Study: NCT06438120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot-based positive psychology intervention
Description: Eight positive psychology exercises will be delivered, including positive introduction, personal strengths, using strengths, three good things, gratitude, hope and optimism, active/constructive responding, and savoring.
Study: NCT06032143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online educational phthalate course
Description: This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control environmental education
Description: Participants in the control group will receive access to environmental exposures other than phthalates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phthalate conversation
Description: Participants in the intervention groups will be asked to engage in conversations about phthalates between doulas/pregnant individuals.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Environmental exposures conversation
Description: Participants in the intervention groups will be asked to engage in conversations about environmental exposures (other than phthalates) between doulas/pregnant individuals.
Study: NCT05022537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retrograde nephrostomy
Description: this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: antegrade nephrostomy
Description: this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
Study: NCT05849480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140 (0.36-1.5 mg/kg; per assigned dose level) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140 (0.36-1.5 mg/kg; per assigned dose level) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
Study: NCT06078345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: 400 Kcal glucose (100g oGTT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: 400 Kcal glucose (100g oGTT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat
Description: 400 Kcal glucose rapeseed oil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat
Description: 400 Kcal glucose rapeseed oil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: 400 Kcal Moltein PURE (111g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: 400 Kcal Moltein PURE (111g)
Study: NCT05679674

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SABR)
Description: 50 Gy in 5 fractions, once per day for 5 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTF)
Description: Participant will use the system for at least 18 hours per day starting on the first day of SABR until abdominal disease progression. Short treatment breaks are permitted for personal needs (such as to take a shower) and during radiation therapy. An additional treatment break is permitted for up to 48 hours every 21 days.
Study: NCT05330988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
Study: NCT04974333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health application on phone
Description: Patients will use a mobile app on their smart phones
Study: NCT04356677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/mL Virazole
Description: 50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/mL Virazole
Description: 100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
Study: NCT05105347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab plus different doses of oral glucocorticosteroid
Description: A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab plus different doses of oral glucocorticosteroid
Description: A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
Study: NCT05444608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast milk olfactory stimulation
Description: Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White noise auditory stimulation
Description: Before the intervention, a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure and will continue to listen for 5 minutes after the procedure.
Study: NCT04672811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study App and Apple Watch
Description: Study App and Apple Watch
Study: NCT05846230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 1291583
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 1291583
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 1291583
Description: Tablet
Study: NCT06316635

Intervention type: PROCEDURE
Intervention: ventilation tube insertion
Description: a paracentesis will be done to tympanic membrane. Glu will be aspirated and trapped.
Study: NCT06387758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low systemic strength training
Description: Low systemic strength training. Youth will complete exercise training for 45 minutes. Eight specific exercises will be performed to target all major muscle groups: calf raises, handgrip, squats, seated row, chest press, plank, low bac extension, and crunches (Table 1). Each exercise involves contractions with moderate load but with an extended duration of up to five minutes.16,17 During each exercise session, youth will have a 5-minute warm up, 5-minute cool down, and be allowed to take rest breaks as needed (minimum 30 seconds). Youth will initially progress by decreasing the number of rest periods and then increasing load. Youth will be provided a 2 lb medicine ball, resistance weight bands, Thera Putty, and a Yoga mat for home exercises. Youth will keep this home exercise equipment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate systemic exercise
Description: Youth assigned to the moderate systemic exercise load group will perform whole-body aerobic exercise at 40-59% of heart rate reserve (HRR) for 45 minutes.76,111 Youth will complete moderate systemic aerobic exercise by walking at a brisk pace and swinging their arms as they walk. Exercise personnel will supervise a 5-minute warm up and 5-minute cool down via videoconferencing and remain on the phone with youth at all times during the walking exercise session. Youth will exercise until the prescribed duration is achieved or until fatigue at which point they will either reduce the intensity or stop until they recover. All training intensities will be based around HRR so it is individualized (not exceeding 59% of HRR). Youth unable to meet the initial training requirements will be slowly progressed over the 8 weeks.
Study: NCT05609396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally enhanced reminder letter
Description: Behavioral interventions to increase FIT-based colorectal cancer screening uptake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally enhanced reminder letter
Description: Behavioral interventions to increase FIT-based colorectal cancer screening uptake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally enhanced reminder letter
Description: Behavioral interventions to increase FIT-based colorectal cancer screening uptake